Diabetes Technology and Therapy in the Pediatric Age Group

Danne T , Limbert C . COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way. Lancet Diabetes Endocrinol. 2020; 8: 465–467.

Bergenstal RM , Garg S , Weinzime SA , et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316: 1407–1408.

Messer LH , Forlenza GP , Sherr JL , et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care, 2018; 41: 789–796.

Lal RA , Basina M , Maahs DM , et al. One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care, 2019; 42: 2190–2196.

Anderzén J , Hermann JM , Samuelsson U , et al. International benchmarking in type 1 diabetes: large difference in childhood HbA1c between eight high-income countries but similar rise during adolescence—a quality registry study. Pediatr Diabetes, 2020; 21: 621–627.

Charalampopoulos D , Hermann JM , Svensson J , et al. Exploring variation in glycemic control across and within eight high-income countries: a cross-sectional analysis of 64,666 children and adolescents with type 1 diabetes. Diabetes Care, 2018; 41: 1180–1187.

Maahs DM , Hermann JM , DuBose SN , et al., DPV Initiative, T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia, 2014; 57: 1578–1585.

Van Name MA , Hilliard ME , Boyle CT , et al. Nighttime is the worst time: parental fear of hypoglycemia in young children with type 1 diabetes. Pediatr Diabetes, 2018; 19: 114–120.

Berget C , Messer LH , Vigers T , et al. Six months of hybrid-closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes, 2020; 21: 310–318.

Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med, 1993; 328: 1676–1685.

Foster NC , Beck RW , Miller KM , et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther, 2019; 21: 66–72.

Tauschmann M , Allen JM , Nagl K , et al. Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multicenter, 3-week, randomized trial. Diabetes Care, 2019; 42: 594–600.

Barnard KD , Hood KK , Weissberg-Benchell J , et al. Psychosocial assessment of artificial pancreas (AP): commentary and review of existing measures and their applicability in AP research. Diabetes Technol Ther, 2015; 17: 295–300.

Hovorka R , Allen JM , Elleri D , et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet, 2010; 375: 743–751.

Elleri D , Allen JM , Nodale M , et al. Automated overnight closed-loop glucose control in young children with type 1 diabetes. Diabetes Technol Ther, 2011; 13: 419–424.

Weinzimer SA , Steil GM , Swan KL , et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care, 2008; 31: 934–939.

Breton MD , Chernavvsky DR , Forlenza GP , et al. Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes Care, 2017; 40: 1644–1650.

Brown SA , Kovatchev BP , Raghinaru D , et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381: 1707–1717.

Tandem Diabetes Care, Inc. Tandem diabetes care announces expanded pediatric indication of the t:slim X2 insulin pump with control-IQ advanced hybrid closed-loop technology, updated June 17, 2020. Available at http://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-expanded-pediatric-indication.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group , Nathan DM , Zinman B , et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med, 2009; 169: 1307–1316.

American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care, 2018; 41: S55–S64.

Cengiz E. Undeniable need for ultrafast-acting insulin: the pediatric perspective. J Diabetes Sci Technol, 2012; 6: 797–801.

Heise T , Pieber TR , Danne T , et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet, 2017; 56: 551–559.

Fath M , Danne T , Biester T , et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes, 2017; 18: 903–910.

Buse JB , Carlson AL , Komatsu M , et al. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. Diabetes Obes Metab, 2018; 20: 2885–2893.

Miller KM , Foster NC , Beck RW , et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care, 2015; 6: 971–978.

Schwandt A , Hermann JM , Rosenbauer J , et al. Longitudinal trajectories of metabolic control from childhood to young adulthood in type 1 diabetes from a large German/Austrian registry: a group-based modeling approach. Diabetes Care, 2017; 40: 309–316.

Blackman SM , Raghinaru D , Adi S , et al. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower A1c levels than injection therapy. Pediatric Diabetes, 2014; 15: 564–572.

Szypowska A , Schwandt A , Svensson J , et al., SWEET Study Group. Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry. Pediatric Diabetes, 2016; 17: 38–45.

DeSalvo DJ , Miller KM , Hermann JM , et al., T1D Exchange and DPV Registries. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV initiative. Pediatr Diabetes, 2018; 19: 1271–1275.

Hofer SE , Raile K , Fröhlich-Reiterer E , et al. Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. J Pediatr, 2014; 165: 956–961 e1–e2.

Samuelsson U , Steineck I , Gubbjornsdottir S . A high mean-HbA1c value 3-15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood—a pilot study using two nation-wide population based quality registries. Pediatr Diabetes, 2014; 15: 229–235.

Hofer SE , Schwandt A , Holl RW , Austrian/ German DPV Initiative . Standardized documentation in pediatric diabetology: experience from Austria and Germany. J Diabetes Sci Technol, 2016; 10: 1042–1049.

Danne T , Lion S , Madaczy L , et al., SWEET group. Criteria for Centers of Reference for pediatric diabetes—a European perspective. Pediatr Diabetes, 2012; 13: 62–75.

Slover RH , Welsh JB , Criego A , et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes, 2012; 13: 6–11.

Beck RW , Riddlesworth T , Ruedy K , et al., DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317: 371–378.

He J , Ryder AG , Li S , et al. Glycemic extremes are related to cognitive dysfunction in children with type 1 diabetes: a meta-analysis. J Diabetes Investig, 2018; 9: 1342–1353.

Cato A , Mauras N , Mazaika P , et al. Longitudinal evaluation of cognitive functioning in young children with T1D over 18 months. J Int Neuropsychol Soc, 2016; 22: 293–302.

Strich D , Balagour L , Shenker J , Gillis D . Lower basal insulin dose is associated with better control in type 1 diabetes. J Pediatr, 2017; 182: 133–136.

Schulten RJ , Piet J , Bruijning PC , de Waal WJ . Lower dose basal insulin infusion has positive effect on glycaemic control for children with type I diabetes on continuous subcutaneous insulin infusion therapy. Pediatr Diabetes, 2017; 18: 45–50.

Pinhas-Hamiel O , Tzadok M , Hirsh G , et al. The impact of baseline hemoglobin A1c levels prior to initiation of pump therapy on long-term metabolic control. Diabetes Technol Ther, 2010; 12: 567–573.

Ramchandani N , Ten S , Anhalt H , et al. Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther, 2006; 8: 663–670.

Thrailkill KM , Moreau CS , Swearingen C , et al. Insulin pump therapy started at the time of diagnosis: Effects on glycemic control and pancreatic β- cell function in type 1 diabetes. Diabetes Technol Ther, 2011; 13: 1023–1030.

Berghaeuser MA , Kapellen T , Heidtmann B , et al., German Working Group for Insulin Pump Treatment in Paediatric Patients. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes, 2008; 9: 590–595.

Shalitin S , Lahav-Ritte T , Lebenthal Y , de Vries L , Phillip M . Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?. Diabetes Technol Ther, 2012; 14: 389–397.

Luyckx K , Seiffge-Krenke I , Schwartz SJ , et al. Identity development, coping, and adjustment in emerging adults with a chronic illness: the sample case of type 1 diabetes. J Adolesc Health, 2008; 43: 451–458.

Dean AJ , Walters J , Hall A . A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness. Arch Dis Child, 2010; 95: 717–723.